Suggestions
Simone Huygens
Health economic researcher and co-owner of Huygens & Versteegh
Simone Huygens is a highly qualified health economic researcher and the co-founder of Huygens & Versteegh, a company specializing in health economic research.1 She has an extensive educational background, having earned a PhD in Health Technology Assessment from Erasmus Universiteit Rotterdam, as well as a Master's degree in Health Economics, Policy and Law, and a Bachelor's degree in Health Policy and Management.
Throughout her career, Simone has held various positions that have contributed to her expertise in the field:
Professional Experience
-
Current Roles:
- Founder and co-owner at Huygens & Versteegh2
- Researcher at the Institute for Medical Technology Assessment
-
Previous Positions:
- PhD student at Erasmus MC
- Research positions at the Institute of Medical Technology Assessment and the Institut Beleid en Management in de Gezondheidszorg
- Research Assistant
- Junior Policy Advisor intern at Albert Schweitzer ziekenhuis
- Student Assistant in Quantitative Research at Erasmus University Rotterdam
Company Information
Huygens & Versteegh, co-founded by Simone Huygens and Matthijs Versteegh, is a company that provides high-quality health economic research services.14 The company was announced in April, as mentioned by Simone in a LinkedIn post.3
Research and Publications
Simone Huygens has contributed to academic publications in the field of health economics. She has co-authored papers on topics such as cost-utility modeling for multiple sclerosis treatment sequences.5
Simone's expertise and dedication to health economic research have established her as a respected professional in the field, with her work spanning academic research, practical applications, and entrepreneurship in the healthcare sector.
Highlights
I am very pleased to announce that our manuscript on the cost-effectiveness of the histology-independent (also called tumour-agnostic) therapy entrectinib is now available online in Value in Health: https://lnkd.in/eipM7FiQ
Evaluating a histology-independent drug was definitely a challenge, but we managed to gain some interesting insights, most importantly: Evaluating a drug without considering the necessary genetic testing procedure can result in completely different reimbursement decisions than when the testing procedure is accounted for in the economic evaluation.
I would like to thank my co-first author Heleen Vellekoop, Matthijs Versteegh, and Maureen Rutten-van Mölken for their dedication to complete this paper: this was a four-man job! Thanks to Irene Santi for her essential help with dealing with one of the main challenges in this project: the estimation of the prognostic value of NTRK-fusions. Of course, I would also like to thank all the partners in the HEcoPerMed consortium (Sarah Wordsworth, Apostolos Tsiachristas, Rositsa Koleva-Kolarova, Balázs Nagy, László Szilberhorn, Tamas Zelei) for the great collaboration in creating this manuscript.
If you are interested in more on this topic, stay tuned for our manuscript on country adaptations of this model in which we evaluated which treatment strategy is most cost-effective in England, Hungary, and the Netherlands.
Het afgelopen jaar heb ik met veel plezier meegewerkt aan de NICER-pilot: een initiatief van iMTA en het ErasmusMC om de kosten en effecten van ziektebeelden met dure geneesmiddelen in kaart te brengen en daarmee artsen, zorginkopers en zorgverzekeraars te informeren over doelmatige keuzes in de zorg.
In deze tijd met veel online meetings hebben we een vernieuwende vorm bedacht om onze resultaten te delen: een live talkshow waarin we onze resultaten bespreken met artsen en een zorginkoper en een website waar de resultaten na afloop op een toegankelijke manier te zien zijn.
Dus komt dat zien op donderdag 22 oktober om 15 uur via onderstaande link! https://lnkd.in/g--7hfv
O.a. met Matthijs Versteegh, Saskia de Groot, Hedwig Blommestein, Margreet Franken, Brenda Leeneman, Peter D., Erik van Raaij, Beatrijs Wokke, Joost Smolders, Ernst Kuipers
